SEC Form 4 · accession 0001104659-18-048864
CYPHERPUNK TECHNOLOGIES INC. · CYPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
HealthCare Ventures IX, L.P.
10% Owner
Healthcare Partners IX, L.P.
10% Owner
Healthcare Partners IX, LLC
10% Owner
Period of report
Jul 30, 2018
Accepted (ET)
Aug 1, 2018 · 7:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001509745
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant (Right to Buy) | $6.085 | Jul 30, 2018 | J | 1,057,769 | D | Nov 14, 2017 | Nov 14, 2024 | Common Stock | 1,057,769 | 0 | D |
Explanation of responses
- F1HealthCare Ventures IX, L.P. ("HCV IX") distributed these warrants to its limited partners on a pro rata basis, for no consideration. In the distribution, Eli Lilly and Company, a 5% or greater stockholder of the Company and limited partner of HCV IX, received a warrant to purchase 331,221 shares of common stock. No shares of outstanding common stock were distributed. HCV IX continues to hold 3,573,376 shares of common stock, which represents 24.3% of the outstanding common stock.